PRELIMINARY AMENDMENT

Attorney Docket No.: Q96125

Application No.: 10/587,398

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the

application:

LISTING OF CLAIMS:

(Original) A method for isolating and culturing multipotent progenitor/stem cells 1.

from cord blood-derived mononuclear cells, which comprises culturing the cord blood-derived

mononuclear cells successively in:

a first animal cell culture medium comprising fetal bovine serum(FBS), L-1)

glutamine and granulocyte macrophage-colony stimulating factor(GM-CSF), in addition to

inorganic salts, vitamins, amino acids and/or supplementary elements;

2) a second animal cell culture medium which is the same as the first animal cell

culture medium except for lacking GM-CSF; and

3) a third animal cell culture medium which is the same as the first animal cell

culture medium except that GM-CSF is replaced with stem cell factor(SCF) and endothelial

growth factor(EGF).

2. (Original) The method of claim 1, wherein the animal cell culture medium further

contains D-glucose ranging from 3,500 to 5,500 mg/Ml and sodium pyruvate ranging from 50 to

200 mg/M ℓ .

PRELIMINARY AMENDMENT

Attorney Docket No.: Q96125

Application No.: 10/587,398

3. (Original) The method of claim 1, wherein the first animal cell culture medium

contains 10 to 20% FBS, 1 to 2 mM L-glutamine, 10 to 100 ng/Mℓ GM-CSF; the second animal

cell culture medium contains 10 to 20% FBS and 1 to 2 mM L-glutamine; and the third animal

cell culture medium contains 10 to 20% FBS, 1 to 2 mM L-glutamine, 10 to 100 mg/Ml SCF

and 10 to 50 mg/M ℓ EGF.

4. (Original) The method of claim 1, wherein the cultivation in the first animal cell

culture medium is conducted by inoculating the mononuclear cells into the first animal cell

culture medium at a concentration of 1×10⁵ to 1×10⁶ cells/cm² and culturing at 37°C under an

atmosphere of 5% CO₂ for 1 to 2 weeks; the cultivation in the second animal cell culture medium

is conducted by replacing the first animal cell culture medium by the second animal cell culture

medium after confirming the formation of a multi-layer cell colony and further culturing at 37°C

under an atmosphere of 5% CO₂ for 1 to 2 weeks; and the cultivation in the third animal cell

culture medium is conducted by inoculating the cells cultured in the second animal cell culture

medium into the third animal cell culture medium at a concentration of 2×10⁴ to 8×10⁴ cells/cm²

after observing the metamorphosis of the multi-layer cell colony into a mono-layer cell colony

and further culturing at 37°C under an atmosphere of 5% CO₂ for 1 to 2 weeks.

5. (Currently amended) A multipotent progenitor/stem cell isolated and cultured

from a cord blood-derived mononuclear cell, according to the method of claim 1, the

multipotent progenitor/stem cell is isolate and cultured by a method comprising

PRELIMINARY AMENDMENT

Attorney Docket No.: Q96125 Application No.: 10/587,398

culturing the cord blood-derived mononuclear cells successively in:

a first animal cell culture medium comprising fetal bovine serum(FBS), L-

glutamine and granulocyte macrophage-colony stimulating factor(GM-CSF), in addition to

inorganic salts, vitamins, amino acids and/or supplementary elements;

a second animal cell culture medium which is the same as the first animal cell

culture medium except for lacking GM-CSF; and

a third animal cell culture medium which is the same as the first animal cell

culture medium except that GM-CSF is replaced with stem cell factor(SCF) and endothelial

growth factor(EGF),

wherein said multipotent progenitor/stem cell has an immunophenotype profile showing

positive reactions against antibodies for CD14, CD31, CD44 and CD45 antigens; negative

reactions against antibodies for CD34, CD62E, CD90(Thy-1) and CD133 antigens; positive and

partial positive reactions against antibodies for CD54 and CD166 antigens; negative and partial

negative reactions against antibodies CD73(SH3, SH4) and CD105(SH2) antigens; and negative

and partial positive reactions against antibodies for CD49a and CD104 antigens.

6. (Canceled)

7. (Original) An animal cell culture medium composition for isolating and culturing

multipotent progenitor/stem cells from cord blood-derived mononuclear cells, which is selected

from the group consisting of:

PRELIMINARY AMENDMENT

Attorney Docket No.: Q96125

Application No.: 10/587,398

an animal cell culture medium composition comprising 10 to 20% FBS, 1 to 2 mM L-

glutamine and 10 to 100 ng/Ml GM-CSF;

an animal cell culture medium composition comprising 10 to 20% FBS and 1 to 2 mM L-

glutamine; and

an animal cell culture medium composition comprising 10 to 20% FBS, 1 to 2 mM L-

glutamine, 10 to 100 mg/Ml SCF and 10 to 50 mg/Ml EGF,

wherein each of the animal cell culture media further contains inorganic salts, amino

acids, vitamins and/or supplementary factors.

8. (Original) The animal cell culture medium composition of claim 7, wherein the

animal cell culture medium further contains D-glucose ranging from 3,500 to 5,500 mg/Mℓ and

sodium pyruvate ranging from 50 to 200 mg/M ℓ .

9. (Original) A method for differentiating multipotent progenitor/stem cells of claim

5 into neurons, which comprises culturing the multipotent progenitor/stem cells in an animal cell

culture medium comprising FBS, L-glutamine, retinoic acid, folskolin, nerve growth

factor(NGF), a supplementary element mixture and beta-mercaptoethanol, in addition to D-

glucose ranging from 3,500 to 5,500 mg/Ml and sodium pyruvate ranging from 50 to 200

 $mg/M\ell$.

PRELIMINARY AMENDMENT

Attorney Docket No.: Q96125

Application No.: 10/587,398

10. (Original) The method of claim 9, wherein the animal cell culture medium

contains 0.1 to 2% FBS, 1 to 2 mM L-glutamine, 1 to 25 µM retinoic acid, 1 to 20 µM folskolin,

10 to 100 ng/Mł NGF, 1×supplementary element mixture and 1×10⁻⁶ and 1×10⁻⁵% beta-

mercaptoethanol.

11. (Original) The method of claim 9, wherein the multipotent progenitor/stem cells

are inoculated into the animal cell culture medium at a concentration ranging from 2×10⁴ to

8×10⁴ cells/cm² and culturing at 37°C under an atmosphere of 5% CO₂ for 1 to 2 weeks.

12. (Original) An animal cell culture medium composition for differentiating

multipotent progenitor/stem cells of claim 5 into neurons, which comprises 0.1 to 2% FBS, 1 to 2

mM L-glutamine. 1 to 25 uM retinoic acid. 1 to 20 uM folskolin. 10 to 100 ng/Ml NGF. 1×

supplementary element mixture and 1×10^{-6} to 1×10^{-5} % beta-mercantoethanol, in addition to D-

glucose ranging from 3,500 to 5,500 mg/Ml and sodium pyruvate ranging from 50 to 200

 $mg/M\ell$.

13. (Original) A method for differentiating multipotent progenitor/stem cells of claim

5 into osteoblasts, which comprises culturing the multipotent progenitor/stem cells in an animal

cell culture medium comprising FBS, dexamethason, ascorbate-2-phosphate and β-

glycerophosphate, in addition to D-glucose ranging from 3,500 to 5,500 mg/Mℓ and sodium

pyruvate ranging from 50 to 200 mg/Ml.

PRELIMINARY AMENDMENT

Attorney Docket No.: Q96125

Application No.: 10/587,398

14. (Original) The method of claim 13, wherein the animal cell culture medium

contains 5 to 20% FBS, 0.1 to 1 µM dexamethasone, 10 to 100 µM ascorbate-2-phosphate and 5

to 20 mM β-glycerophosphate.

(Original) The method of claim 13, wherein the multipotent progenitor/stem cells 15.

are inoculated into the animal cell culture medium at a concentration ranging from 5×10^4 to

2×10⁵ cells/cm² and culturing at 37°C under an atmosphere of 5% CO₂ for 2 to 3 weeks.

16. (Original) An animal cell culture medium composition for differentiating

multipotent progenitor/stem cells of claim 5 into osteoblasts, which comprises 5 to 20% FBS, 0.1

to 1 μM dexamethasone, 10 to 100 μM ascorbate-2-phosphate and 5 to 20 mM β -

glycerophosphate, in addition to D-glucose ranging from 3,500 to 5,500 mg/Mℓ and sodium

pyruvate ranging from 50 to 200 mg/M ℓ .

17. (Original) A method for differentiating multipotent progenitor/stem cells of claim

5 into endothelial cells, which comprises culturing the multipotent progenitor/stem cells in an

animal cell culture medium comprising FBS and vascular endothelial growth factor(VEGF), in

addition to D-glucose ranging from 3,500 to 5,500 mg/Ml and sodium pyruvate ranging from 50

to 200 mg/M ℓ .

PRELIMINARY AMENDMENT

Attorney Docket No.: Q96125

Application No.: 10/587,398

18. (Original) The method of claim 17, wherein the animal cell culture medium

contains 0.1 to 2% FBS and 10 to 100 ng/Mℓ VEGF.

19. (Original) The method of claim 17, wherein the multipotent progenitor/stem cells

are inoculated into the animal cell culture medium at a concentration ranging from 1×10⁵ to

4×10⁵ cells/cm² and culturing at 37°C under an atmosphere of 5% CO₂ for 2 to 3 weeks.

20. (Original) An animal cell culture medium composition for differentiating

multipotent progenitor/stem cells of claim 5 into endothelial cells, which comprises 0.1 to 2%

FBS and 10 to 100 ng/Mℓ VEGF, in addition to D-glucose ranging from 3,500 to 5,500 mg/Mℓ

and sodium pyruvate ranging from 50 to 200 mg/M ℓ .

21. (Original) A method for differentiating multipotent progenitor/stem cells of claim

5 into myoblasts, which comprises culturing the multipotent progenitor/stem cells in an animal

cell culture medium comprising bovine serum albumin(BSA) and 5-azacytidine, in addition to

D-glucose ranging from 3,500 to 5,500 mg/Mℓ and sodium pyruvate ranging from 50 to 200

 $mg/M\ell$.

(Original) The method of claim 21, wherein the animal culture medium contains 22.

5 to 10% BSA and 10 to 20 µM 5- azacytidine.

PRELIMINARY AMENDMENT

Attorney Docket No.: Q96125

Application No.: 10/587,398

23. (Original) The method of claim 21, wherein the multipotent progenitor/stem cells

are inoculated into the animal cell culture medium at a concentration ranging from 1×10⁵ to

5×10⁵ cells/cm² and culturing at 37°C under an atmosphere of 5% CO₂ for 5 to 6 weeks.

24. (Original) An animal cell culture medium composition for differentiating

multipotent progenitor/stem cells of claim 5 into myoblasts, which comprises 5 to 10% BSA and

10 to 20 μM 5- azacytidine, in addition to D-glucose ranging from 3,500 to 5,500 mg/Mℓ and

sodium pyruvate ranging from 50 to 200 mg/M ℓ .

25. (Original) A method for differentiating multipotent progenitor/stem cells of claim

5 into hepatocytes, which comprises culturing the multipotent progenitor/stem cells in an animal

cell culture medium comprising hepatocyte growth factor(HGF), oncostatin M and L-glutamine,

in addition to D-glucose ranging from 3,500 to 5,500 mg/Mℓ and sodium pyruvate ranging from

50 to 200 mg/M ℓ .

26. (Original) The method of claim 25, wherein the animal cell culture medium

contains 10 to 100 ng/Ml HGF, 5 to 50 ng/Ml oncostatin M and 1 to 2 mM L-glutamine.

27. (Original) The method of claim 25, wherein the multipotent progenitor/stem cells

are inoculated into the animal cell culture medium at a concentration ranging from 5×10^4 to

5×10⁵ cells/cm² and culturing at 37°C under an atmosphere of 5% CO₂ for 2 to 4 weeks.

PRELIMINARY AMENDMENT

Attorney Docket No.: Q96125

Application No.: 10/587,398

28. (Original) An animal cell culture medium composition for differentiating

multipotent progenitor/stem cells of claim 5 into hepatocytes, which comprises 10 to 100 ng/Ml

HGF, 5 to 50 ng/Mℓ oncostatin M and 1 to 2 mM L-glutamine, in addition to D-glucose ranging

from 3,500 to 5,500 mg/M ℓ and sodium pyruvate ranging from 50 to 200 mg/M ℓ .

29. (Original) A method for differentiating multipotent progenitor/stem cells of claim

5 into dendritic cells, which comprises the steps of: culturing the multipotent progenitor/stem

cells in a first animal cell culture medium comprising FBS, L-glutamine, GM-CSF and

interleukin-4(IL-4) for inducing immature differentiation; transferring the immature

differentiated cells in a second animal cell culture medium comprising FBS, L-glutamine, tumor

necrosis factor-α(TNF-α), IL-1β, IL-6 and prostaglandin E2; and culturing them for inducing

mature differentiation, wherein each of the animal cell culture media further contains D-glucose

ranging from 3,500 to 5,500 mg/M ℓ and sodium pyruvate ranging from 50 to 200 mg/M ℓ .

30. (Original) The method of claim 29, wherein the first animal cell culture medium

contains 1 to 2% FBS, 1 to 2 mM L-glutamine, 10 to 1,000 ng/Ml GM-CSF and 10 to 100

ng/Mℓ IL-4, and the second animal cell culture medium contains 1 to 2% FBS, 1 to 2 mM L-

glutamine, 1 to 100 ng/M ℓ TNF- α , 1 to 2 ng/M ℓ IL-1 β , 100 to 1,000 U/M ℓ IL-6 and 0.1 to 10

μg/Mℓ prostaglandin E2.

PRELIMINARY AMENDMENT

Attorney Docket No.: Q96125

Application No.: 10/587,398

31. (Original) The method of claim 29, wherein the multipotent progenitor/stem cells

are inoculated into the first animal cell culture medium at a concentration ranging from 1×10^5 to

1×10⁷ cells/cm² and culturing at 37°C under an atmosphere of 5% CO₂ for 3 to 15 days, and the

immature differentiated cells are culture in the second animal cell culture medium at 37°C under

an atmosphere of 5% CO₂ for 1 to 7 days.

32. (Original) An animal cell culture medium composition for differentiating

multipotent progenitor/stem cells of claim 5 into dendritic cells, which is selected from the group

consisting of:

an animal cell culture medium composition for inducing immature differentiation

comprising 1 to 20% FBS, 1 to 2 mM L-glutamine, 10 to 1,000 ng/Mℓ GM-CSF and 10 to 100

ng/Mℓ IL-4; and

an animal cell culture medium composition for inducing mature differentiation

comprising 1 to 20% FBS, 1 to 2 mM L-glutamine, 1 to 100 ng/Mℓ TNF-α, 1 to 100 ng/Mℓ IL-

1 β , 100 to 10,000 U/M ℓ IL-6 and 0.1 to 10 ug/M ℓ prostaglandin E2,

wherein each of the animal cell culture media further contains D-glucose ranging from

3,500 to 5,500 mg/M ℓ and sodium pyruvate ranging from 50 to 200 mg/M ℓ .

33. (Original) A cell composition for a cell therapy comprising the multipotent

progenitor/stem cell of claim 5.

PRELIMINARY AMENDMENT

Attorney Docket No.: Q96125 Application No.: 10/587,398

34. (Original) The cell composition of claim 33, which is used for treating

Parkinson's disease, Alzheimer's diseases, quadriplegia resulting from spinal cord injury,

leukemia, apoplexy, encephalophyma, juvenile-onset diabetes, cardiac infarction,

hepatocirrhosis, muscle diseases, cardiomuscular diseases, liver diseases, blood diseases, the

disruption and permanent functional disorder of osteoblasts and chondrocytes.